Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Williams, Richard T

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. [electronic resource] - Proceedings of the National Academy of Sciences of the United States of America Apr 2006 - 6688-93 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

0027-8424

10.1073/pnas.0602030103 doi


Alleles
Animals
Antineoplastic Agents--pharmacology
B-Lymphocytes--drug effects
Benzamides
Bone Marrow Transplantation
Cyclin-Dependent Kinase Inhibitor p16
Genes, abl
Hematopoietic Stem Cells--drug effects
Humans
Imatinib Mesylate
Interleukin-7--pharmacology
Leukemia, Lymphoid--drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Neoplasm Transplantation
Piperazines--pharmacology
Pyrimidines--pharmacology
Tumor Cells, Cultured
Tumor Suppressor Protein p14ARF--deficiency